Table 4 Hazard ratios for developing cancer in patients with CHI after excluding HBV/HCV coinfected patients

Overall

1,517

829

2.34

(2.15–2.55)^‡

1,174

731

2.71

(2.47–2.99)^‡

Brain cancer

21

4

0.85

(0.29–2.51)

13

4

1.51

(0.48–4.77)

Head and neck cancer

233

47

0.84

(0.61–1.16)

107

29

1.06

(0.70–1.62)

Thyroid gland cancer

53

20

1.41

(0.84–2.38)

23

9

1.62

(0.73–3.61)

Esophageal cancer

42

13

1.47

(0.78–2.76)

22

9

2.08

(0.93–4.65)

Stomach cancer

78

18

1.01

(0.60–1.69)

76

23

1.38

(0.85–2.24)

Colorectal cancer

212

72

1.51

(1.15–1.98)^†

204

51

1.09

(0.79–1.49)

Liver cancer

102

439

18.9

(15.2–23.6)^‡

86

451

23.28

(18.4–29.5)^‡

Gallbladder and extrahepatic bile duct cancer

20

7

1.56

(0.65–3.73)

19

11

2.53

(1.17–5.48)*

Pancreatic cancer

33

13

1.69

(0.88–3.23)

32

11

1.68

(0.82–3.41)

Lung cancer

198

48

1.07

(0.78–1.47)

212

43

0.87

(0.62–1.21)

Kidney cancer

52

22

1.81

(1.10–3.01)*

47

11

0.98

(0.49–1.93)

Bladder cancer

67

13

0.87

(0.48–1.58)

65

13

0.91

(0.50–1.68)

Uterine and corpus cancer^b

33

11

1.26

(0.63–2.50)

25

8

1.61

(0.71–3.67)

Cervical cancer^b

42

10

1.10

(0.55–2.21)

32

11

1.52

(0.75–3.08)

Ovarian cancer^b

23

8

1.35

(0.60–3.07)

10

1

0.58

(0.07–4.62)

Prostate cancer^c

96

22

0.93

(0.58–1.49)

82

16

0.84

(0.48–1.46)

Breast cancer^b

192

53

1.15

(0.84–1.56)

92

25

1.24

(0.78–1.95)

Melanoma

11

0

--

--

7

2

1.48

(0.29–7.56)

Skin cancer

27

13

1.90

(0.97–3.73)

24

9

1.35

(0.61–2.99)

Non-Hodgkin’s lymphoma

29

15

2.22

(1.18–4.18)*

27

13

2.66

(1.34–5.27)^†

Myeloma

9

2

1.04

(0.22–4.90)

5

3

3.25

(0.73–14.5)

Leukemia

35

10

1.24

(0.61–2.52)

22

2

0.35

(0.08–1.53)